Insurance services company CNO Financial Group (NYSE: CNO) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 5.5% year on year to $1.01 billion. Its non-GAAP profit of $1.26 per share was 29.9% above analysts’ consensus estimates.

Is now the time to buy CNO? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

CNO Financial Group’s second quarter was marked by strong sales growth and margin expansion, leading to a positive market reaction. Management attributed the outperformance to record annuity and Medicare Supplement sales, as well as continued success in the company’s captive agent distribution model. CEO Gary Bhojwani highlighted, “Our exclusive middle market focus and last-mile captive agent distribution remain key competitive advantages.” The quarter also benefited from favorable underwriting and investment results, while targeted marketing shifts in the life insurance business allowed for more efficient acquisition channels.

Looking ahead, CNO’s guidance is shaped by confidence in sustained demand for its health and retirement products, particularly due to demographic tailwinds from the baby boomer cohort entering retirement. Management expects continued growth in Medicare Supplement and annuity products, supported by its diversified product portfolio and multi-channel distribution. CFO Paul McDonough noted, “Our intention is to improve ROE each year, including in 2027 and beyond, with the ultimate goal of achieving top quartile ROE relative to our peer group.” The company also anticipates ongoing investments in technology modernization and disciplined capital deployment to further support growth.

Key Insights from Management’s Remarks

Management pointed to the company’s diversified product portfolio, agent productivity, and shifting consumer preferences as the main drivers behind CNO’s robust quarter and improved outlook.

• Agent distribution model strength: CNO’s captive agent force, which focuses on the middle-income market, was cited as a major contributor to sales growth and resilience against competitive pressures. Management believes this model is difficult for competitors to replicate and allows for consistent customer engagement.

• Medicare Supplement tailwinds: The company achieved a 52% increase in Medicare Supplement new annualized premiums, driven by a shift in consumer preference away from Medicare Advantage plans. This product acts as a “door opener” for broader customer relationships and supports cross-selling other retirement and health products.

• Worksite channel momentum: The worksite division saw a 29% jump in life and health new annualized premiums, benefiting from both geographic expansion and deeper penetration within existing markets. Employers are increasingly offering employee-paid voluntary benefits, and CNO’s product suite is designed to meet these needs.

• Investment income contribution: CNO’s investment portfolio generated 8% growth in net investment income, helped by higher yields and alternative investment returns. The portfolio’s allocation to corporate bonds and a continued focus on asset quality were highlighted by Chief Investment Officer Eric Johnson.

• Expense discipline and capital deployment: The expense ratio remained favorable, partly due to timing, and capital was allocated toward technology modernization, share repurchases, and maintaining liquidity. Management indicated continued focus on reinvestment and selective inorganic growth opportunities.

Drivers of Future Performance

CNO’s full-year outlook is supported by favorable industry demographics, continued sales momentum in Medicare and annuities, and ongoing investments in distribution and technology.

• Favorable demographic trends: The company expects the retirement of thousands of baby boomers daily to sustain demand for Medicare and annuity products. Management views this demographic shift as a durable, long-term growth driver, with 11,000 Americans turning 65 each day.

• Technology and operational investments: Ongoing investments in technology modernization initiatives—especially upgrading core applications and infrastructure—are intended to improve efficiency and reduce operational risk, with management expecting these efforts to enhance sales productivity and customer service.

• Capital management and risk balancing: Management is focused on maintaining a strong capital position, deploying excess capital through disciplined share repurchases, and seeking selective inorganic growth. Continued attention to product risk balancing across mortality, morbidity, and longevity aims to ensure consistent profitability.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will monitor (1) the pace and sustainability of Medicare Supplement and annuity sales growth, (2) execution of technology modernization and its impact on agent productivity, and (3) capital deployment decisions, especially regarding share repurchases and potential inorganic growth. Any regulatory developments affecting capital management or retirement product offerings will also be closely watched.

CNO Financial Group currently trades at $55.24, up from $53.49 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.